Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Boston Scientific Announces Results For Fourth Quarter And Full Year 2021

      Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation)

      News provided by

      Boston Scientific Corporation

      Feb 02, 2022, 06:30 ET

      Share this article

      Share this article


      MARLBOROUGH, Mass., Feb. 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational1 basis and 15.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $80 million or $0.06 per share (EPS), compared to $196 million or $0.14 per share a year ago and achieved adjusted EPS of $0.45 for the period, compared to $0.23 a year ago.

      For the full year 2021, the company generated net sales of $11.888 billion, growing 19.9 percent on a reported basis, 18.7 percent on an operational basis and 18.9 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income (loss) available to common stockholders of $985 million or $0.69 per share, compared to $(115) million or $(0.08) per share a year ago, and delivered full year adjusted EPS of $1.63, compared to $0.96 a year ago.

      "I'm very pleased with our strong fourth quarter and full year results, thanks to our team's commitment and resilience in a challenging environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "I'm excited about the capabilities we've built, and I remain confident in our ability to execute in 2022 and against our long-range plans as we continue delivering meaningful innovations for patients around the world."

      Fourth quarter financial results and recent developments:

      • Reported net sales of $3.127 billion, representing an increase of 15.4 percent on a reported basis, compared to the company's guidance range of 13 to 17 percent; 16.9 percent on an operational basis; and 15.1 percent on an organic basis, compared to the company's guidance range of 12 to 16 percent, all compared to the prior year period.
      • Reported GAAP net income available to common stockholders of $0.06 per share, compared to the company's guidance range of $0.21 to $0.23 per share, and achieved adjusted EPS of $0.45 per share, compared to the guidance range of $0.43 to $0.45 per share.
      • Achieved net sales growth in each reportable segment4, compared to the prior year period:
        • MedSurg: 12.1 percent reported, 13.3 percent operational and 9.4 percent organic
        • Rhythm and Neuro: 11.8 percent reported, 13.2 percent operational and 6.1 percent organic
        • Cardiovascular: 25.3 percent reported, 27.0 percent operational and organic
      • Achieved the following regional5 net sales growth, compared to the prior year period:
        • U.S.: 19.7 percent reported and operational
        • EMEA (Europe, Middle East and Africa): 12.3 percent reported and 16.0 percent operational
        • APAC (Asia-Pacific): 14.3 percent reported and 17.4 percent operational
        • Emerging Markets3: 30.2 percent reported and 31.6 percent operational
      • Initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System consists of two cardiac rhythm management devices intended to work together to coordinate therapy: the EMBLEM™ MRI Subcutaneous Implantable Defibrillator System and the EMPOWER™ Modular Pacing System, designed to be the first leadless pacemaker capable of delivering both bradycardia pacing support and antitachycardia pacing (ATP).
      • Presented positive late-breaking clinical trial data on the COMBO randomized control trial at the 2022 North American Neuromodulation Society (NANS) meeting demonstrating the durable effectiveness of the WaveWriter™ Spinal Cord Stimulator (SCS) System, capable of delivering combination therapy for the treatment of chronic pain, designed to offer more opportunities to customize SCS therapy and optimize outcomes.
      • Completed acquisition of Devoro Medical Inc., developer of the WOLF Thrombectomy® Platform, an innovative non-console and lytic-free technology which rapidly captures and removes blood clots, complementing the company's full suite of interventional strategies for thromboemboli.
      • Commenced limited market release of the AXIOS™ Stent in China. The device gives physicians the ability to endoscopically manage two serious complications from pancreatitis: symptomatic pseudocysts and walled-off pancreatic necrosis.
      • Secured from the U.S. Centers for Medicare and Medicaid Services (CMS) a higher-paying Ambulatory Payment Classification for Rezūm™ Water Vapor Therapy, resulting in a national Medicare average payment increase of ~75 percent when performed as a hospital outpatient procedure or in an ambulatory surgical center for the treatment of benign prostatic hyperplasia (enlarged prostate). Data have confirmed the therapy as an effective, long-term solution for the condition, which affects about half of all men by age 60.
      • The Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy guidelines for hepatocellular carcinoma (HCC) were updated to include transarterial radioembolization (Y-90), which encompasses TheraSphere™ Y-90 Glass Microspheres, for very early stage (0) and early stage (A) patients. The recommendations--which are commonly cited to guide clinical-decision making--were updated based on the results of the LEGACY study, which also led to FDA approval of TheraSphere for treatment of HCC.
      • Received multiple recognitions for corporate social responsibility and employee engagement, including number one health care equipment and services company in the JUST 100 rankings of America's largest public companies by JUST Capital and CNBC; inclusion among Glassdoor's Best Places to Work in 2022; and the Catalyst award for the company's Creating Equal Opportunities for Growth initiative, a global effort to accelerate career advancement and address barriers faced by women and multicultural talent.

      1.  Operational net sales growth excludes the impact of foreign currency fluctuations.

      2.  Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.

      3. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales.

      4. We have three historical reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices).

      5.  On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business. Our consolidated net sales include Specialty Pharmaceuticals up to the date of the closing of the transaction. Specialty Pharmaceuticals net sales were substantially U.S. based and presented as a stand-alone operating segment alongside our Medical Device reportable segments.

      Q4 Net Sales by Business and Region:







      Change



      Three Months Ended
      December 31,


      Reported Basis


      Less: Impact
      of Foreign Currency Fluctuations


      Operational Basis


      Less: Impact
      of Recent Acquisitions / Divestitures


      Organic Basis

      (in millions)

      2021

      2020







         Endoscopy

      $558

      $515


      8.3%


      (1.5)%


      9.8%


      —%


      9.8%


         Urology and Pelvic Health

      441

      376


      17.2%


      (0.8)%


      18.0%


      9.2%


      8.7%


      MedSurg

      999

      892


      12.1%


      (1.2)%


      13.3%


      3.9%


      9.4%


         Cardiac Rhythm Management

      514

      451


      14.0%


      (1.5)%


      15.5%


      11.0%


      4.5%


         Electrophysiology

      100

      85


      18.1%


      (2.8)%


      20.9%


      5.3%


      15.6%


         Neuromodulation

      244

      232


      5.2%


      (0.6)%


      5.8%


      —%


      5.8%


      Rhythm and Neuro

      858

      767


      11.8%


      (1.4)%


      13.2%


      7.0%


      6.1%


         Interventional Cardiology

      808

      585


      38.2%


      (1.9)%


      40.1%


      —%


      40.1%


         Peripheral Interventions

      462

      429


      7.6%


      (1.4)%


      9.0%


      —%


      9.0%


      Cardiovascular

      1,270

      1,014


      25.3%


      (1.7)%


      27.0%


      —%


      27.0%


      Medical Devices4

      3,127

      2,673


      17.0%


      (1.4)%


      18.4%


      3.3%


      15.1%


      Specialty Pharmaceuticals5

      —

      36


      (100.0)%


      —%


      (100.0)%


      (100.0)%


      —%

      Net Sales

      $3,127

      $2,708


      15.4%


      (1.4)%


      16.9%


      1.8%


      15.1%











      Change



      Three Months
      Ended December 31,


      Reported
      Basis


      Less: Impact
      of Foreign
      Currency
      Fluctuations


      Operational

       Basis

      (in millions)

      2021

      2020





      U.S.

      $1,798

      $1,502


      19.7%


      —%


      19.7%


      EMEA

      662

      590


      12.3%


      (3.7)%


      16.0%


      APAC

      559

      489


      14.3%


      (3.1)%


      17.4%


      Latin America and Canada

      107

      91


      17.9%


      (0.9)%


      18.8%


      Medical Devices4

      3,127

      2,673


      17.0%


      (1.4)%


      18.4%


      Specialty Pharmaceuticals5

      —

      36


      (100.0)%


      —%


      (100.0)%


      Net Sales

      $3,127

      $2,708


      15.4%


      (1.4)%


      16.9%












      Emerging Markets3

      $398

      $306


      30.2%


      (1.4)%


      31.6%












      Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.




      Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions / divestitures are not prepared in accordance with U.S. GAAP.











      Full Year Net Sales by Business and Region:







      Change



      Year Ended December 31,


      Reported Basis


      Less: Impact of Foreign Currency Fluctuations


      Operational Basis


      Less: Impact of Recent Acquisitions / Divestitures


      Organic Basis

      (in millions)

      2021

      2020







         Endoscopy

      $2,141

      $1,780


      20.3%


      1.3%


      18.9%


      —%


      18.9%


         Urology and Pelvic Health

      1,583

      1,286


      23.1%


      1.0%


      22.1%


      2.8%


      19.2%


      MedSurg

      3,724

      3,066


      21.4%


      1.2%


      20.2%


      1.2%


      19.0%


         Cardiac Rhythm Management

      2,019

      1,704


      18.5%


      1.4%


      17.1%


      9.5%


      7.7%


         Electrophysiology

      365

      287


      27.4%


      1.6%


      25.8%


      2.3%


      23.5%


         Neuromodulation

      909

      761


      19.5%


      0.9%


      18.6%


      —%


      18.6%


      Rhythm and Neuro

      3,293

      2,752


      19.7%


      1.3%


      18.4%


      6.1%


      12.3%


         Interventional Cardiology

      3,038

      2,299


      32.2%


      1.5%


      30.7%


      —%


      30.7%


         Peripheral Interventions

      1,820

      1,577


      15.4%


      1.2%


      14.2%


      —%


      14.2%


      Cardiovascular

      4,858

      3,876


      25.3%


      1.4%


      23.9%


      —%


      23.9%


      Medical Devices4

      11,875

      9,694


      22.5%


      1.3%


      21.2%


      2.1%


      19.1%


      Specialty Pharmaceuticals5

      13

      219


      (93.9)%


      0.1%


      (94.0)%


      (49.6)%


      (44.4)%

      Net Sales

      $11,888

      $9,913


      19.9%


      1.3%


      18.7%


      (0.3)%


      18.9%




















      Change



      Year Ended

      December 31,


      Reported
      Basis


      Less: Impact
      of Foreign
      Currency
      Fluctuations


      Operational

       Basis

      (in millions)

      2021

      2020





      U.S.

      $6,901

      $5,508


      25.3%


      —%


      25.3%


      EMEA

      2,518

      2,097


      20.0%


      3.7%


      16.4%


      APAC

      2,070

      1,781


      16.2%


      2.3%


      13.9%


      Latin America and Canada

      386

      307


      25.6%


      2.3%


      23.3%


      Medical Devices4

      11,875

      9,694


      22.5%


      1.3%


      21.2%


      Specialty Pharmaceuticals5

      13

      219


      (93.9)%


      0.1%


      (94.0)%


      Net Sales

      $11,888

      $9,913


      19.9%


      1.3%


      18.7%












      Emerging Markets3

      $1,429

      $1,138


      25.5%


      3.2%


      22.3%












      Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.




      Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of  acquisitions / divestitures are not prepared in accordance with U.S. GAAP.











      Guidance for Full Year and Q1 2022

      The company estimates net sales growth for the full year 2022, versus the prior year period, to be in a range of approximately 6 to 8 percent on both a reported basis and organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.94 to $1.04 and adjusted EPS, excluding certain charges (credits) of  $1.73 to $1.79.

      The company estimates net sales growth for the first quarter of 2022, versus the prior year period, to be in a range of approximately 5 to 8 percent on both a reported and organic basis. First quarter organic guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.16 to $0.20 and adjusted EPS, excluding certain charges (credits) of $0.38 to $0.40. 

      Conference Call Information

      Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

      About Boston Scientific 
      Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

      Cautionary Statement Regarding Forward-Looking Statements 
      This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend," and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the first quarter and full year 2022; our financial performance; our business plans and product performance; and the impact of the COVID-19 pandemic on the company's results of operations. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

      Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

      Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

      Use of Non-GAAP Financial Information 
      A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

      CONTACT:





      Media:

      Kate Haranis


      Investors:

      Lauren Tengler


      508-683-6585 (office)



      508-683-4479 (office)


      Media Relations



      Investor Relations


      Boston Scientific Corporation



      Boston Scientific Corporation


      [email protected]



      [email protected]

      BOSTON SCIENTIFIC CORPORATION

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (Unaudited)



      Three Months Ended

      December 31,


      Year Ended

      December 31,

      in millions, except per share data

      2021

      2020


      2021

      2020













      Net sales

      $            3,127

      $            2,708


      $          11,888

      $            9,913

      Cost of products sold

      971

      1,000


      3,711

      3,465

      Gross profit

      2,155

      1,708


      8,177

      6,448







      Operating expenses:






      Selling, general and administrative expenses

      1,153

      1,027


      4,359

      3,787

      Research and development expenses

      320

      286


      1,204

      1,143

      Royalty expense

      11

      14


      49

      45

      Amortization expense

      192

      194


      741

      789

      Goodwill impairment charges

      —

      73


      —

      73

      Intangible asset impairment charges

      197

      8


      370

      460

      Contingent consideration expense (benefit)

      (18)

      2


      (136)

      (100)

      Restructuring charges (credits)

      23

      36


      40

      52

      Litigation-related charges (credits)

      128

      18


      430

      278

      Gains on disposal of businesses and assets

      (30)

      —


      (78)

      —


      1,975

      1,658


      6,978

      6,528

      Operating income (loss)

      180

      50


      1,199

      (80)







      Other income (expense):






      Interest expense

      (87)

      (96)


      (341)

      (361)

      Other, net

      26

      352


      218

      362

      Income (loss) before income taxes

      120

      306


      1,076

      (79)

      Income tax expense (benefit)

      26

      96


      36

      2

      Net income (loss)

      $                  94

      $                210


      $             1,041

      $                (82)

      Preferred stock dividends

      (14)

      (14)


      (55)

      (33)

      Net income (loss) available to common stockholders

      $                  80

      $                196


      $                985

      $              (115)







      Net income (loss) per common share - basic

      $               0.06

      $               0.14


      $               0.69

      $             (0.08)

      Net income (loss) per common share - assuming dilution

      $               0.06

      $               0.14


      $               0.69

      $             (0.08)







      Weighted-average shares outstanding






      Basic

      1,425.2

      1,427.7


      1,422.3

      1,416.7

      Assuming dilution

      1,436.2

      1,440.6


      1,433.8

      1,416.7

      BOSTON SCIENTIFIC CORPORATION

      NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

      (Unaudited)



      Three Months Ended December 31, 2021

      in millions, except per share data

      Gross Profit

      Operating Expenses

      Operating Income (Loss)

      Other
      Income
      (Expense)

      Income (Loss) Before Income Taxes

      Net
      Income
      (Loss)

      Preferred Stock Dividends

      Net Income (Loss) Available to Common Stockholders

      Impact per Share(1)

      Reported

      $        2,155

      $         1,975

      $               180

      $                (60)

      $             120

      $               94

      $              (14)

      $                   80

      $            0.06

      Non-GAAP adjustments:










      Amortization expense

      —

      (192)

      192

      —

      192

      180

      —

      180

      0.13

      Goodwill and other intangible asset impairment
      charges

      —

      (197)

      197

      —

      197

      171

      —

      171

      0.12

      Acquisition / divestitures-related net charges (credits)

      32

      (19)

      50

      (57)

      (7)

      (4)

      —

      (4)

      (0.00)

      Restructuring and restructuring-related net charges (credits)

      20

      (39)

      58

      —

      58

      51

      —

      51

      0.04

      Litigation-related net charges (credits)

      —

      (128)

      128

      —

      128

      98

      —

      98

      0.07

      Investment impairment net charges (credits)

      —

      —

      —

      2

      2

      2

      —

      2

      0.00

      EU MDR implementation costs

      9

      (5)

      14

      —

      14

      13

      —

      13

      0.01

      Deferred tax expenses (benefits)

      —

      —

      —

      —

      —

      46

      —

      46

      0.03

      Discrete tax items

      —

      —

      —

      —

      —

      16

      —

      16

      0.01

      Adjusted

      $        2,216

      $         1,396

      $               819

      $             (115)

      $             704

      $             667

      $              (14)

      $                 653

      $            0.45











      (1) For the three months ended December 31, 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders.












      Three Months Ended December 31, 2020

      in millions, except per share data

      Gross Profit

      Operating Expenses

      Operating Income (Loss)

      Other
      Income
      (Expense)

      Income (Loss) Before Income Taxes

      Net
      Income
      (Loss)

      Preferred Stock Dividends

      Net Income (Loss) Available to Common Stockholders

      Impact per Share(1)

      Reported

      $        1,708

      $         1,658

      $                 50

      $               256

      $             306

      $             210

      $              (14)

      $                 196

      $            0.14

      Non-GAAP adjustments:










      Amortization expense

      —

      (194)

      194

      —

      194

      169

      —

      169

      0.12

      Intangible asset impairment charges

      —

      (81)

      81

      —

      81

      81

      —

      81

      0.06

      Acquisition / divestiture-related net charges (credits)

      25

      (24)

      48

      —

      48

      16

      —

      16

      0.01

      Restructuring and restructuring-related net charges (credits)

      17

      (77)

      94

      —

      94

      80

      —

      80

      0.06

      Litigation-related net charges (credits)

      —

      (18)

      18

      —

      18

      6

      —

      6

      0.00

      Investment impairment net charges (credits)

      —

      —

      —

      (363)

      (363)

      (280)

      —

      (280)

      (0.19)

      EU MDR implementation costs

      7

      (2)

      9

      —

      9

      8

      —

      8

      0.01

      Deferred tax expenses (benefits)

      —

      —

      —

      —

      —

      14

      —

      14

      0.01

      Discrete tax items

      —

      —

      —

      —

      —

      48

      —

      48

      0.03

      Adjusted

      $        1,757

      $         1,261

      $               495

      $             (108)

      $             388

      $             351

      $              (14)

      $                 337

      $            0.23











      (1) For the three months ended December 31, 2020 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders.











      An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.











      BOSTON SCIENTIFIC CORPORATION

      NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

      (Unaudited)



      Year Ended December 31, 2021

      in millions, except per share data

      Gross Profit

      Operating Expenses

      Operating
      Income
      (Loss)

      Other Income (Expense)

      Income (Loss) Before Income Taxes

      Net
      Income
      (Loss)

      Preferred Stock Dividends

      Net Income
      (Loss)
      Available to
      Common
      Stockholders

      Impact per Share(1)

      Reported

      $        8,177

      $         6,978

      $           1,199

      $           (123)

      $         1,076

      $         1,041

      $              (55)

      $                   985

      $            0.69

      Non-GAAP adjustments:










      Amortization expense

      —

      (741)

      741

      —

      741

      676

      —

      676

      0.47

      Goodwill and other intangible asset impairment
      charges

      —

      (370)

      370

      —

      370

      318

      —

      318

      0.22

      Acquisition / divestitures-related net charges (credits)

      65

      34

      31

      (482)

      (450)

      (453)

      —

      (453)

      (0.32)

      Restructuring and restructuring-related net charges (credits)

      79

      (112)

      191

      —

      191

      169

      —

      169

      0.12

      Litigation-related net charges (credits)

      —

      (430)

      430

      —

      430

      331

      —

      331

      0.23

      Investment impairment net charges (credits)

      —

      —

      —

      181

      181

      137

      —

      137

      0.10

      EU MDR implementation costs

      32

      (17)

      49

      —

      49

      45

      —

      45

      0.03

      Deferred tax expenses (benefits)

      —

      —

      —

      —

      —

      132

      —

      132

      0.09

      Discrete tax items

      —

      —

      —

      —

      —

      (5)

      —

      (5)

      (0.00)

      Adjusted

      $        8,353

      $         5,343

      $           3,010

      $           (423)

      $         2,587

      $         2,391

      $              (55)

      $               2,336

      $            1.63











      (1) For the year ended December 31, 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders.












      Year Ended December 31, 2020

      in millions, except per share data

      Gross Profit

      Operating Expenses

      Operating
      Income
      (Loss)

      Other Income (Expense)

      Income (Loss) Before Income Taxes

      Net
      Income
      (Loss)

      Preferred Stock Dividends

      Net Income
      (Loss)
      Available to
      Common
      Stockholders

      Impact per Share(1)

      Reported

      $        6,448

      $         6,528

      $                (80)

      $                  1

      $              (79)

      $              (82)

      $              (33)

      $                 (115)

      $          (0.08)

      Non-GAAP adjustments:










      Amortization expense

      —

      (789)

      789

      —

      789

      701

      —

      701

      0.49

      Intangible asset impairment charges

      —

      (533)

      533

      —

      533

      465

      —

      465

      0.32

      Acquisition / divestiture-related net charges (credits)

      122

      (75)

      198

      (1)

      196

      115

      —

      115

      0.08

      Restructuring and restructuring-related net charges (credits)

      64

      (107)

      171

      —

      171

      146

      —

      146

      0.10

      Litigation-related net charges (credits)

      —

      (278)

      278

      —

      278

      261

      —

      261

      0.18

      Investment impairment net charges (credits)

      —

      —

      —

      (429)

      (429)

      (331)

      —

      (331)

      (0.23)

      EU MDR implementation costs

      21

      (7)

      29

      —

      29

      25

      —

      25

      0.02

      Deferred tax expenses (benefits)

      —

      —

      —

      —

      —

      41

      —

      41

      0.03

      Discrete tax items

      —

      —

      —

      —

      —

      69

      —

      69

      0.05

      Adjusted

      $        6,655

      $         4,738

      $           1,917

      $           (429)

      $         1,488

      $         1,411

      $              (33)

      $               1,378

      $            0.96











      (1) For the year ended December 31, 2020, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net loss and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating EPS. We have assumed dilution of 13.8 million common stock equivalents related to employee stock options for all or a portion of the non-GAAP adjustments, which were anti-dilutive for GAAP purposes due to our net loss position.


      An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.











       

      BOSTON SCIENTIFIC CORPORATION

      Q1 and FY 2022 GUIDANCE RECONCILIATIONS

      (Unaudited)


      Net Sales



      Q1 2022 Estimate


      Full Year 2022 Estimate


      (Low)

      (High)


      (Low)

      (High)

      Reported growth

      5%

      8%


      6%

      8%

      Less: Impact of foreign currency fluctuations

      (2)%

      (2)%


      (1)%

      (1)%

      Operational growth

      7%

      10%


      7%

      9%

      Less: Impact of certain acquisitions / divestitures

      2%

      2%


      1%

      1%

      Organic growth

      5%

      8%


      6%

      8%







      Earnings per Share



      Q1 2022 Estimate


      Full Year 2022 Estimate


      (Low)

      (High)


      (Low)

      (High)

      GAAP results

      $           0.16

      $           0.20


      $           0.94

      $           1.04







      Amortization expense

      0.11

      0.11


      0.45

      0.45

      Acquisition / divestiture-related net charges (credits)

      0.04

      0.03


      0.10

      0.08

      Restructuring and restructuring-related net charges (credits)

      0.03

      0.02


      0.08

      0.07

      Other adjustments

      0.04

      0.04


      0.15

      0.14

      Adjusted results

      $           0.38

      $           0.40


      $           1.73

      $           1.79

      Use of Non-GAAP Financial Measures

      To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share (EPS) that exclude certain amounts; operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

      To calculate adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share we exclude certain charges (credits) from GAAP net income (loss) and GAAP net income (loss) available to common stockholders. Amounts are presented after-tax at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission or any Quarterly Report on Form 10-Q that we file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

      The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) available to common stockholders and GAAP net income (loss) per common share - assuming dilution, respectively. 

      To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

      Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

      Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

      We believe that presenting adjusted net income (loss), adjusted net income (loss) available to common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

      SOURCE Boston Scientific Corporation

      Modal title

      Also from this source

      Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes

      Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes

      Boston Scientific Corporation (the "Company") (NYSE: BSX) announced today that it has priced a public offering of $3,000,000,000 aggregate principal...

      SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

      Boston Scientific Corporation (NYSE: BSX) today announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.